Brind.

CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.

2 reports, 1 independent Updated Sun 00:00
No new developments lately
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.

Who's involved

What this event is mainly about
CRISPR TherapeuticsVertex PharmaceuticalsFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA expanded Casgevy approval to younger patients; Vertex gets 60% revenue, and Cathie Wood bought shares.1 source
  2. Casgevy, a gene therapy, received FDA approval from CRISPR and Vertex.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped